

PHARMACEUTICAL CAPSULES

ACGcaps™ HI

C CELLULOSE



Make it better.

An HPMC capsule for dry powder inhalation.

Developed after extensive studies on powder retention, ACGcaps™ HI has been specifically engineered for use with sustainable (no propellant) dry powder inhalation devices. ACGcaps™ HI ensures accurate dosing, uniform dispersion, and efficient drug delivery to the respiratory system, enhancing drug effectiveness and patient outcomes.

Key features

- / Low powder retention for maximum dose delivery
- / Proven puncturing, cutting and twist-open performance
- / Compatible with several dry powder inhalation devices
- / Suitable for a wide range of active pharmaceutical ingredients
- / Proven machine-friendly design
- / Complies with stringent regulatory requirements for microbiological limits




Technical specifications

- / % Powder retention: not more than 1.0%
- / Moisture content: 3.0% to 8.0%
- / Microbial limit: not more than 100 CFU

ACGcaps™ HR and ACGcaps™ HI were carefully filled with the same powder and their surfaces examined under a scanning electron microscope.

The microscopic image of ACGcaps™ HR shows extensive powder adhesion and accumulation on its surface, forming distinct clusters and patches. In contrast, the surface of ACGcaps™ HI appears smoother and cleaner, and revealing minimal powder retention on its surface. This ensures that dry powder formulations will be effectively delivered to the lungs.

EM magnification



These certifications are applicable to certain colours and / or variants.